Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo medication + placebo alcohol Clear all
Completed Phase 1 Interventional

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

NCT04721691
View directory record Official record
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
Epidiolex 100 mg/mL Oral Solution, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

NCT00773422
View directory record Official record
Conditions
Smoking
Interventions
naltrexone, varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 13, 2026, 9:24 AM EDT
Withdrawn Not applicable Interventional

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT00741767
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions
salmeterol-fluticasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

NCT04565288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
14 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug /Cue Interactions In Alcohol-Tobacco Comorbidity

NCT00816231
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Tobacco, Alcoholic Beverage, Placebo
Behavioral · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

NCT02291016
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Formoterol, Placebo
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 13, 2026, 9:24 AM EDT
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Topiramate to Aid Smoking Cessation in Alcohol Dependent Men

NCT00802412
View directory record Official record
Conditions
Nicotine Dependence, Alcohol Dependence
Interventions
Topiramate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
View directory record Official record
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 13, 2026, 9:24 AM EDT
Not listed Phase 4 Interventional

Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement

NCT01651962
View directory record Official record
Conditions
Labor Pain
Interventions
Terbutaline, Fentanyl, 0.9% NaCl
Drug
Lead sponsor
Kai Schoenhage
Other
Eligibility
18 Years to 53 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
View directory record Official record
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Combined Treatment for Alcohol-Dependent Individuals With PTSD

NCT00262223
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions
Seeking Safety, Sertraline, Pill placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Early Phase 1 Interventional

Propranolol in Primary Progressive Aphasia

NCT06066710
View directory record Official record
Conditions
Aphasia, Primary Progressive
Interventions
Propranolol, Magnetic Resonance Imaging (MRI), Placebo
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

NCT00439374
View directory record Official record
Conditions
Preterm Delivery, Cervical Length
Interventions
17 alpha-hydroxyprogesterone caproate, Placebo Oil
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

NCT00981617
View directory record Official record
Conditions
Alcohol Dependence
Interventions
ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Tucson, Arizona • Cerritos, California • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
342
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavior Brain Responses

NCT03964350
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions
Ethanol, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 13, 2026, 9:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

NCT02724761
View directory record Official record
Conditions
Dysphagia, Dysphonia, Postoperative Pain
Interventions
Racemic Epinephrine, Placebo (for racemic epinephrine)
Drug
Lead sponsor
Andrew Chung
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 13, 2026, 9:24 AM EDT
Not listed Not applicable Interventional

Neuroma Injections to Treat Restless Legs Syndrome - RCT

NCT00656110
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml, Normal saline - 1ml
Drug
Lead sponsor
Lowcountry Infectious Diseases
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2009 · Synced Oct 13, 2026, 9:24 AM EDT